Affimed Provides Update on ASCO AFM13-104 Oral Presentation
May 06 2022 - 4:02PM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, today announced that the
American Society of Clinical Oncology (ASCO) has informed the
Company’s collaborator that it has removed the previously announced
oral presentation on AFM13-104, the investigator sponsored trial
that evaluates AFM13 pre-complexed with NK cells in patients with
relapsed/refractory CD30-positive lymphomas, from the upcoming
conference program.
Per ASCO, the decision was solely based on its embargo policy
which restricts data in submitted abstracts from presentation at
any prior conference or forum. Data from AFM13-104 was recently
presented in an oral session at the Annual Meeting of the American
Association for Cancer Research (AACR) on April 10, 2022, in New
Orleans, Louisiana.
The removal of the presentation is not related to the status or
results of the ongoing trial. Affimed respects ASCO’s decision and
is working with The University of Texas MD Anderson Cancer Center
on plans to submit additional data on AFM13-104 to a future
scientific forum.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to give patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander FudukidisDirector, Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin Vice President, Marketing and
CommunicationsE-Mail: m.sandin@affimed.com Tel.: +1 (484)
888-8195
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024